1 / 12

Response to pandemic (H1N1)2009: experience from China

Response to pandemic (H1N1)2009: experience from China. Yuelong Shu Chinese National Influenza Center National Institute for Viral Disease Control and Prevention China CDC 200 9 - 8-19, Beijing. Response and Strategy. Timely development of diagnostic kits Quarantine and case management

colette-austin
Download Presentation

Response to pandemic (H1N1)2009: experience from China

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Response to pandemic (H1N1)2009: experience from China Yuelong Shu Chinese National Influenza Center National Institute for Viral Disease Control and Prevention China CDC 2009-8-19, Beijing

  2. Response and Strategy • Timely development of diagnostic kits • Quarantine and case management • Changed with the different situation • Enhanced Surveillance: • Network laboratories • Sentinel hospitals • Vaccine development • Communication and education

  3. Diagnostic kits development • the diagnostic kits were made based on USCDC design after USCDC provided the primer and probe sequence on May 1, and then distributed to all network labs • new diagnostic kits were developed according to the virus sequence from the USCDC

  4. Preparation USCDC real-time PCRkit timeline

  5. Distribution of Diagnostic Kit (Design by USCDC/Self design) • National Influenza network laboratories( 411) • Quarantine system Laboratories • Laboratories in military system • Macao SAR • Other countries: 12 countries

  6. Objectives of national influenza surveillance network expansion • Monitor the antigenic and genetic characterization of the pandemic H1N1 virus : still match the vaccine strain? • Monitor any reassortant or mutation of the pandemic H1N1 virus: more severe or/and transmissible? • Monitor the antiviral drug susceptibility : the antiviral drugs still useful for the treatment and/or prophylaxis?

  7. Surveillance Net work expansion: 411network laboratories and 536 sentinel hospitals since June, 2009, comparing with 63 labs and 197 sentinel hospitals before

  8. Timeline of capacity improvement of National Influenza Surveillance Network 556 sentinel hospitals, 63 old NLs & 161 NLs at the first phase with the PCR detection capacity started surveillance TheNLs without the test capacity will conduct lab surveillance in the NLs with the test capacity Regular vaccines All 411 NLs have the capacity for PCR detection of pandemic H1N1 virus Sep. 30 Aug. 30 Aug. 15

  9. The lab and hospital numbers which already started the surveillance Hospitals which already report ILI labs which already conduct PCR detection

  10. Vaccine development • China CDC coordinated the clinical trails in mainland of china • 10 vaccine companies involved • Including whole inactive vaccine, and split vaccine with/without adjuvant, 2 doses immunization • Different antigen amount per dose ( 7.5ug-30 ug) • More than 10 thousands volunteers involved

  11. Thank You!

More Related